HERSCHORN, S.; NAZIR, J.; RAMOS, B.; HAKIMI, Z. Supplementary data: Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada. Canadian Urological Association Journal, [S. l.], v. 11, n. 3-4, p. E129–33, 2017. DOI: 10.5489/cuaj.4617. Disponível em: https://cuaj.ca/index.php/journal/article/view/4617. Acesso em: 2 may. 2024.